57801-65-7

Basic information

• Product Name: 4-(oxazol-4-yl)phenol
• Synonyms: 4-(oxazol-4-yl)phenol
• CAS NO: 57801-65-7
• Molecular Formula: C₉H₇NO₂
• Molecular Weight: 161.15738
• Mol File: 57801-65-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(oxazol-4-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(oxazol-4-yl)phenol(57801-65-7)
• EPA Substance Registry System: 4-(oxazol-4-yl)phenol(57801-65-7)

Safety Data

• Hazardous Substances Data: 57801-65-7(Hazardous Substances Data)

Upstream product

• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 54289-74-6 4-(4-methoxyphenyl)oxazole 

Downstream Products

• 53242-57-2 2-hydroxy-5-oxazol-4-yl-benzoic acid 
• 1578263-59-8 C₂₂H₁₉N₃O₄ 

Relevant articles and documents

SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human β3-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the β3-

Method for enhancement of chemiluminescence

A method for enhancing chemiluminescence which uses a heterocyclic compound of the formula: STR1 wherein R1 is an oxygen or sulfur atom or an imino group optionally substituted by 4-hydroxyphenyl, and R2, R3 and R4 are a hydrogen or halogen atom, an optionally substituted hydrocarbon residue, a heterocyclic group or the like in a luminescence system.

Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids

We have made a series of 4- and 5-aryl- and 4- and 5-heteroarylsalicylic acid derivatives with the objective of reducing gastric irritation and increasing potency. Here we describe a series of 4- and 5-heterocyclic salicylic acids and their antiinflammatory-analgesic potencies measured in comparison to aspirin. An improvement of the therapeutic index over aspirin of 100 was achieved; however, the heterocyclic salicylic acids lacked antipyretic activity. Some physicochemical parameters which may bear on the antiinflammatory activity of these compounds are discussed.